關(guān)鍵詞搜索：
3D細(xì)胞培養(yǎng)相關(guān)產(chǎn)品，多肽毒素，原代細(xì)胞，細(xì)胞因子，抗體，試劑盒，各類細(xì)菌、病毒熒光定量PCR試劑盒，轉(zhuǎn)基因檢測(cè)儀器和耗材等。
insphero公司聯(lián)合蘇黎世大學(xué)的骨科研究實(shí)驗(yàn)室、化學(xué)和生物化學(xué)研究所，應(yīng)用insphero 3D細(xì)胞懸滴培養(yǎng)板，構(gòu)建3D骨肉瘤模型。
文章“An in vitro osteosarcoma 3D microtissue model for drug development”于2014年11月10號(hào)發(fā)表于 Journal of Biotechnology上
（鏈接地址：http://www.ncbi.nlm.nih.gov/pubmed/25234575）
作者介紹：
Markus Rimanna, 1, Sandra Laternsera, 1, Ana Gvozdenovicb, Roman Muffb, Bruno Fuchsb, Jens M. Kelmc, Ursula Graf-Hausnera, ,
a Institute of Chemistry and Biological Chemistry (ICBC), Zurich University of Applied Sciences, Waedenswil, Switzerland
b Laboratory for Orthopedic Research, Department of Orthopedics, University of Zurich, Switzerland
c InSphero AG, Schlieren, Switzerland
文章亮點(diǎn)：
1.Microtissues (3D) from three different osteosarcoma cell lines were developed.
取三種不同的骨肉瘤細(xì)胞系（SaOS-2、HOS和MG-63細(xì)胞），采用insphero 3D細(xì)胞懸滴培養(yǎng)板構(gòu)建3D骨肉瘤微組織
2. Microtissues from patient-derived osteosarcoma were produced.
骨肉瘤細(xì)胞系（SaOS-2、HOS和MG-63細(xì)胞），均取自成骨肉瘤和軟骨肉瘤病人
3.Inherent osteosarcoma tissue heterogeneity was shown with different microtissues.
不同的微組織，會(huì)顯示出骨肉瘤固有的組織異質(zhì)性
4.Five drug responses were analysed in 3D showing differences compared to 2D.
用五種藥物（阿霉素、順鉑、?；橇_定、培美曲塞、紫杉醇）對(duì)3D骨肉瘤微組織用藥，實(shí)驗(yàn)結(jié)果是不同于常規(guī)2D細(xì)胞培養(yǎng)的
總結(jié)：
The 3D microtissues reflect the tissue heterogeneity of OS and are potential suitable tools for drug development towards personalised medicine
3D微組織能夠反映出骨肉瘤（OS）固有的組織異質(zhì)性，它將成為藥物開(kāi)發(fā)以及走向個(gè)人化醫(yī)療過(guò)程中的有潛力工具。
